A Phase 4 interventional study of Arm 1 Oral Cortico Steroids in Upper Respiratory Tract Infection and Asthma, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by University of British Columbia · Phase 4, Interventional, and Prevention
The purpose of this study is to investigate the benefits of giving filled prescription of a medication to be used upon early onset of symptoms of URTI induced asthma. The hope is to reduce the need to present to Health Care centres for treatment.
In Canada, asthma affects more the 12% of children. Exacerbation are a common feature of asthma. In children, upper respiratory tract infection (URTI's) are responsible for over 80% of asthma exacerbation.
Experts in asthma care acknowledge this critical problem and have developed guidelines to reduce asthma exacerbation.
The criteria for participation in this study to have 2 or more presentations to a Health Service centre in the past 12 months for URTI induced asthma. These patients will be followed and interviewed monthly over a 12 month period to investigate whether the use of Oral cortico-steroids upon early onset of URTI induced asthma prevents the need for presentation to hospital
1,031 studies on the registry are indexed under Respiratory Tract Infections; 144 are open to participants now.
This study's enrollment of 92 is below the median of 199 across 698 interventional studies indexed under Respiratory Tract Infections.
Browse Respiratory Tract Infections studies →University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A filled prescription will be given to be used upon early onset of symptoms.
Drug: Arm 1 Oral Cortico Steroids
monitor the readmission of URTI induced asthma in children over a 12 month period
Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs. Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Also known as: Prednisone
Reduction of representation to Health Services for Exacerbation of URTI induced asthma
To review the effect of medication given at early onset of symptoms have on reducing the presentation to Health Services and Emergency Departments.
Time frame: One year
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia